Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04227288 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT04227288: Completed Phase 4 study, sponsored by University of Alabama at Birmingham.
NCT04227288 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04227288, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
Primary Outcome
The target nail will be defined as the nail that has the highest nail thickness score at baseline. This nail will remain the target nail for the remainder of the study. Number of participants achieving clinical improvement as measure by the nail thickness (hyperkeratosis) measurement at week 24 compared to baseline.
Interventions
- DRUG Enstilar Foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 4 |
What the finished NCT04227288 record still lists
NCT04227288 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Enstilar Foam is the first listed.
NCT04227288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04227288 about?
NCT04227288 is a clinical study titled "A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis". The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
What is the current status of trial NCT04227288?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2021-11-01. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT04227288?
The interventions under investigation include: Enstilar Foam (DRUG).
Who is sponsoring clinical trial NCT04227288?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04227288's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI